Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Document › Details

SolasCure Ltd.. (6/3/24). "Press Release: SolasCure Selected for Innovate UK Global Incubator Programme in Houston". Cambridge.

Region Region Houston, TX
  Country United States (USA)
Organisations Organisation SolasCure Ltd.
  Organisation 2 Texas Medical Centre (TMC)
Products Product Aurase® Wound Gel
  Product 2 business development (state/region)
Persons Person Harle, Lee (SolasCure 202406 CEO)
  Person 2 Jeffery, Sarah (Zyme Communications 201504)
     


> Programme delivered in partnership with the Texas Medical Centre

> Programme will support Aurase Wound Gel for future entry into US market, advancing SolasCure’s mission to transform chronic wound care for millions of patients worldwide


SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, today announced it has been selected for Innovate UK’s Global Incubator Programme in Houston, US. The programme, which is focused on commercialising innovative solutions for unmet healthcare needs, is delivered in partnership with the Texas Medical Centre (TMC), the largest medical complex globally. The programme will support the future entry of Aurase Wound Gel, SolasCure’s first investigational product for the treatment of millions of patients with chronic wounds worldwide, into the US market.

SolasCure is one of 16 healthcare companies selected for the Global Incubator Programme in Houston. The Company’s participation in the programme builds on the recent European Innovation Council’s Accelerator Grant and Innovate UK Biomedical Catalyst Grant wins to further advance the development of Aurase Wound Gel.

The 6-month Global Incubator Programme is fully funded by Innovate UK and includes two intensive market visits to Houston, a dynamic health research hub with over 1,760 life science companies, healthcare facilities and research institutions. These visits will focus on customer discovery, mentorship, and investor networking, including engagement with hospital administrators, procurement, and reimbursement professionals, to support the future entry of Aurase Wound Gel for the US market.

"It is a real boost to our journey at SolasCure to be selected for this Global Incubator Programme, continuing the momentum from our recent EIC Accelerator and the BMC grant wins. This represents another key piece of industry validation and recognition by TMC/TMC-Innovation, global leaders in medical innovation, that SolasCure has the potential to address a huge unmet need," commented Lee Harle, Chief Executive Officer of SolasCure. "TMC is the largest medical complex in the world and gaining access to this expertise and network will be invaluable in strengthening our plans for SolasCure and Aurase Wound Gel in the US."


For more information about SolasCure, please visit: https://solascure.com/.


Contacts

Sarah Jeffery
Zyme Communications
Tel: +44 (0) 7771 730919
Email: sarah.jeffery@zymecommunications.com


About SolasCure Ltd https://solascure.com/

SolasCure is a pioneering biologics company committed to addressing the pressing issue of inadequate debridement and healing solutions for chronic wounds. Our product, Aurase Wound Gel addresses a significant unmet medical need - better wound bed preparation is a growing and urgent problem without safe and effective solutions. This innovative approach incorporates biomimicry of medical maggots' natural processes that clean wounds and promote healing. We aim to provide accessible solutions across all settings from hospital to home care.

SolasCure was founded in 2017 as a spin-off from BRAIN Biotech AG, a leading German biotech company focused on harnessing biological diversity to develop innovative solutions.

SolasCure is headquartered in Cambridge, UK.

Follow SolasCure on LinkedIn @SolasCure


About Innovate UK www.innovateuk.ukri.org

Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions.

Innovate UK is part of UK Research and Innovation. For more information visit www.innovateuk.ukri.org


About Texas Medical Center https://www.tmc.edu/

Texas Medical Center (TMC) — the largest medical complex in the world is at the forefront of advancing life sciences. Housing the brightest medical minds, its 50 million sq. ft. campus annually serves 10 million patients, conducts 180,000+ surgeries, 750,000 ER visits, 14,000 heart surgeries, and delivers 25,000+ babies.

The TMC Accelerator offers emerging digital health and medical device pioneers access to the world’s largest medical city. It’s the prime hub for international firms, as TMC’s clinical, business, and expert insights shape market entry, growth, and commercialisation strategies. Since 2015, TMC has dedicatedly supported startups aiming to expand in the US.

   
Record changed: 2024-07-04

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for SolasCure Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants 650x300px




» top